Objective: To examine outcomes at age 4.5 years and compare to earlier ages in children with fetal antiepileptic drug (AED) exposure.
Antiepileptic drugs (AEDs) are among the most common potentially teratogenic drugs taken by women of childbearing potential. Animal studies have demonstrated that fetal AED exposure at doses lower than those required for anatomic malformations can produce behavior deficits. 1, 2 Our group initiated a prospective study to establish if such effects can occur in humans. We have previously reported differential effects of fetal AED exposure on cognitive outcomes in children at age 3 years. 3 Based largely on the data from this report, the Food and Drug Administration recently released a drug safety communication reporting an increased risk of impaired cognitive development in children whose mothers took valproate during pregnancy. 4 Since deficits at age 3 years might change with maturation, we examined the effects of fetal AED exposure on cognitive functions at age 4.5 years and compared these findings to outcomes at ages 2 and 3 years.
METHODS Design. The Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) study is an ongoing prospective observational investigation, which enrolled pregnant women with epilepsy who were on AED monotherapy (i.e., carbamazepine, lamotrigine, phenytoin, or valproate) from October 1999 through February 2004 across 25 epilepsy centers in the United States and United Kingdom. Sample sizes were estimated to detect a 0.5 SD in IQ outcome. These AEDs were the most frequently prescribed during pregnancy at our centers during enrollment. No other AEDs were employed in sufficient numbers to allow adequate sample sizes for analysis. Polytherapy was not included because of prior reports of poorer outcomes. 5, 6 A nonexposed control group was not included at the direction of the NIH review panel. This is a planned interim analysis.
Standard protocol approvals, registrations, and patient consents. Institutional review boards at each center approved the study, and written informed consent was obtained prior to enrollment according to the Declaration of Helsinki. Study conduct and patient safety were monitored by an NIH appointed Data Safety Management Board. The study is registered at clinicaltrials.gov as NCT00021866.
Participants. Pregnant women with epilepsy on the 4 monotherapies were enrolled. Since maternal IQ is the major predictor of child IQ in population studies, 7 mothers with IQ Ͻ70 were excluded to avoid floor effects. Other exclusion criteria included positive syphilis or HIV serology, progressive cerebral disease, other major disease (e.g., diabetes), exposure to teratogenic agents other than AEDs, poor AED compliance, drug abuse in the prior year, or drug abuse sequelae.
Procedures. Information was collected on potentially confounding variables, including maternal IQ, age, education, employment, race/ethnicity, seizure/epilepsy types and frequency, AED dosages, compliance, other medicines, socioeconomic status, 8 UK/US site, preconception folate use, use of alcohol, tobacco, or other drugs during pregnancy, unwanted pregnancy, abnormalities and complications in present or prior pregnancies, enrollment and birth gestational age, birthweight, breastfeeding, and childhood medical diseases. Cognitive outcomes were evaluated by assessors (blinded to AED) using the Differential Ability Scales (DAS) 9 at ages 3 and 4.5, and Bayley Scales of Infant Development (BSID) 10 at age 2. Testing for age 4.5 outcomes ranged from 51 to 61 months of age. Standardized scores were calculated. Separate investigations with very similar designs in the United States and United Kingdom were merged after initiation. Maternal IQs were determined by different measures due to later merger: Test of Nonverbal Intelligence-third edition (TONI-3) 11 in 267 mothers (67 UK), Wechsler Abbreviated Scale of Intelligence (WASI) 12 in 20 (all UK), and National Adult Reading Test (NART) 13 in 17 (all UK). Training and monitoring of neuropsychological evaluations were conducted to assure quality and consistency. Workshops were conducted for neuropsychological test batteries annually, and each assessor was required to identify errors and provide appropriate correction for videotaped testing sessions containing errors in administration and scoring. Assessors also had to submit videotape of their practice test session with record forms to the Neuropsychology Core for review, feedback, and approval. If assessors failed, they submitted additional video assessments for approval.
Therapeutic dosages (mg/day) vary across AEDs. In order to allow comparisons across AEDs, average AED dose during pregnancy was standardized, as in our prior report, 3 relative to ranges observed within each AED group in the intent-to-treat popula-tion by the following calculation: 100 ϫ (observed dose Ϫ minimum dose) Ϭ range of doses (i.e., maximum Ϫ minimum).
Statistical analysis. The primary analysis was intent-to-treat (n ϭ 310 live births including 6 twin pairs). Secondary analysis was performed on children who completed testing at age 4.5 years (n ϭ 209 including 6 twin pairs). Secondary analyses also included comparison to outcomes at ages 2 and 3 years, correlations of age 4.5 IQ to standardized doses and to maternal IQ for each AED, propensity score analyses, and comparison of verbal and nonverbal performances at age 4.5 years. Analyses were performed at the NEAD Data and Statistical Center using SAS and R.
For the primary analysis, linear regression models were used to examine group differences in IQ adjusting for maternal IQ, standardized AED dose, maternal and gestational age at delivery, years maternal education, race/ethnicity (self-reported), and alcohol use during pregnancy. Additional covariates examined were epilepsy/seizure types, seizure frequency during pregnancy, employment, socioeconomic status, US/UK site, tobacco use, birthweight, unwanted pregnancy, breastfeeding, prior pregnancy birth defects and complications, present pregnancy complications, AED compliance, and other medications used (most common in descending order were vitamins, non-narcotic analgesics, narcotics, antibiotics, iron, antiemetics, antacids, and local anesthetics). Our a priori hypothesis was that specific AED, dose, and maternal IQ were important covariates, so these were included as predictors in a linear model with child IQ as outcome. Other covariates were added individually to the model and were included if found to be significant ( p Ͻ 0.05), or if they did not exhibit collinearity with existing predictors. When added to the model, none of the baseline variables substantively changed inferences regarding AED group differences.
For the intent-to-treat analysis, Markov Chain Monte Carlo methods were used to impute missing age 4.5 outcomes from available age 2 and 3 outcomes and from baseline variables related to outcome or missingness. 14, 15 Baseline variables in the imputation model included AED, dose, maternal IQ and age, gestational age at delivery, years of maternal education, alcohol use, race/ethnicity, and socioeconomic status (SES). Mothers of children with missing age 4.5 outcomes differed significantly from the rest on maternal IQ, years of maternal education, and SES ( p Ͻ 0.05, t test for continuous variables, Fisher exact test for categorical variables). They had lower IQ, fewer years of education, and lower SES. These variables were included in the imputation model. Standard errors and confidence intervals of parameter estimates incorporated imputation uncertainty. Least squares mean IQs were estimated for each group adjusting for maternal IQ, maternal age, dose, gestational age, years maternal education, alcohol use, and race/ethnicity. Similar secondary analyses, without imputations for missing cognitive data, were conducted for the completer sample (i.e., children with cognitive testing at 4.5 years).
To investigate whether baseline differences in seizure type or other characteristics explain the association of valproate with poorer cognitive outcomes, post hoc subgroup analyses were conducted and forest plots were created. Subgroups were defined by 1) seizure type and 2) propensity scores. 16 Further description of our propensity analysis approach is available in our prior report. 3 To test the probability that the proportion of children with marked impairment of cognition (i.e., IQ Ͻ 70) is unchanged across time, Cochran Q statistic was used to test the null hypothesis using the sample of children with cognitive testing at all 3 ages (i.e., 2, 3, and 4.5 years). To test for differences across AEDs in % IQ Ͻ70 at age 4.5, Fisher exact test was used.
RESULTS
The primary intent-to-treat analysis included 304 mothers and 310 live births (6 sets of twins). Mean gestational age at enrollment was 18 weeks (range 4 -37), which did not differ across drugs. The secondary completer analysis included 203 mothers and 209 children (6 sets of twins). Baseline maternal characteristics for the intent-to-treat sample were given in our prior publication, 3 and for age 4.5 completers are depicted in table 1. Statistical results for the primary intent-to-treat and completer analyses with age 4.5 IQ as the dependent variable in the linear regression analyses are in table 2. Because different measures were used to estimate maternal IQ, a covariate for type of maternal IQ measure was added to the primary model; this covariate was nonsignificant (p ϭ 0.39). In addition, reanalysis of the completer group analysis using only those with maternal TONI measure yielded results similar to the original analyses.
Adjusted mean age 4.5 IQ scores along with 95% confidence intervals (CIs) for each AED group are listed in table 3 for the intent-to-treat and completer analyses. Children exposed in utero to valproate had significantly lower mean IQ than each of the other AEDs. Scatterplots and correlations (figure 1) depict the relationship of age 4.5 IQ with standardized dose. Dose-dependent effects were present for valproate but not for other AEDs. Similar results were found for separate analyses using first and third trimester dosages. Child and maternal IQ were significantly related for each AED except valproate (figure e-1 on the Neurology ® Web site at www.neurology.org). Verbal abilities were significantly lower than nonver- bal abilities across all drugs combined and for each AED (table 4) . Age 4.5 IQ correlated with age 2 BSID (r ϭ 0.66, p Ͻ 0.0001) and age 3 DAS IQ (r ϭ 0.77, p Ͻ 0.0001). Adjusted mean cognitive scores (BSID and DAS IQ) and % marked intellectual impairment (Ͻ70 standard score) are in table e-1 for each AED across ages 2, 3, and 4.5 years for all children tested at each age and for those tested at all 3 ages. Overall, mean IQ scores improved ( p Ͻ 0.0001) and % marked intellectual impairment decreased ( p ϭ 0.0037) as children became older. From age 3 to 4.5, IQ improved for carbamazepine ( p ϭ 0.008), lamotrigine ( p Ͻ 0.0001), and phenytoin ( p ϭ 0.002), but not valproate ( p ϭ 0.57). At age 4.5, 10% of children exposed to valproate had marked intellectual impairment compared to 0%-4% for other AEDs ( p ϭ 0.0064); this AED difference was also present in the subset of children tested at all 3 time points ( p ϭ 0.0007).
Propensity score analysis demonstrates that the results are not due to differences in baseline variables related to either the child IQ outcome or chances of belonging to the valproate group. The forest plot displaying means by seizure type and AED group shows that AED group differences cannot be explained by imbalances in underlying seizure type (figure e-2). A subanalysis of patients with juvenile myoclonic epilepsy did not alter the results. The analysis examining sensitivity of results to missing data demonstrated that the results cannot be explained by incomplete data.
DISCUSSION
The present age 4.5 year results are consistent with our prior findings, 3 and demonstrate reduced cognitive abilities in children exposed in utero to valproate monotherapy. Similar to our age 3 year findings, 3 valproate dose was associated with lower child IQ at age 4.5, but the dose of the other AEDs was not. In addition, maternal IQ was associated with child IQ at age 4.5 for each AED except valproate, similar to our age 3 finding. 3 Our findings are consistent with other studies reporting impaired cognition in children with fetal valproate exposure. [17] [18] [19] [20] [21] [22] The present results add confidence to our prior results, and also add new findings. Since age 4.5 outcomes are related significantly to age 2 and 3 outcomes, impairments may be detected early facilitating appropriate intervention programs. Cognitive improvements occurred as children aged. It is possible that this improvement could be due at least in part to practice effects. However, a different test was use at age 2 vs 3 and 4.5. Further, improvement did not appear to occur in valproate exposed children, in which 10% of the children had marked intellectual impairment range (i.e., Ͻ70 IQ) at age 4.5. If practice effects are occurring, they do not appear to be present in the valproate group.
Higher maternal IQ was associated with higher child IQ overall and for carbamazepine, lamotrigine, and phenytoin individually, but not for valproate. Greater maternal education and age were both associated with higher child IQ; lower child IQ was seen in very young mothers. Lower gestational age and maternal alcohol use were both associated with lower Table 2 Results for linear regression analysis with age 4.5 IQ as dependent variable for intent-to-treat analysis (n ‫؍‬ 310 children) and completer analysis (n ‫؍‬ 209 children) child IQ. Child IQ was higher in Caucasians. Similar results were found in our completer analysis. The prospective design, blinded cognitive assessments using standardized measures, and detailed monitoring of multiple potential confounding factors are strengths of our study. Limitations include a relatively small non-population-based sample, loss of enrolled subjects to analysis, lack of randomization, lack of AED blood levels, and absence of an unexposed control group during pregnancy. Another weakness of our study is that different measures were used to estimate maternal IQ. However, the maternal IQ measures used in our study correlate well with a standard adult IQ measure (i.e., full-scale IQ of the Wechsler Adult Intelligence Scale). [11] [12] [13] Further, regression analyses controlling for type of maternal IQ measure and analysis of the completer sample limited to mothers receiving the TONI both produce similar results. A potential confounding issue for observational studies is that differences in baseline characteristics might affect child IQ and alter results. However, the observed associations persist in analyses adjusted for baseline characteristics, including propensity scores and seizure type.
We previously reported that all 4 of these commonly used AEDs impair verbal abilities compared to nonverbal abilities at age 3. 23 Here, we find that this verbal deficit persists for all 4 AEDs at age 4.5 years. The verbal and nonverbal measures are expressed as standard scores, so these scores should be equal based on normed data in healthy children. Performance IQ is more susceptible to practice effects than verbal IQ. 24, 25 Although practice effects could affect the cognitive outcomes, it is unlikely that such an effect is a major factor in our findings. The 30-day practice effects on the DAS for the verbal and nonverbal cluster scores are modest, 9 and our test-retest interval was 1.5 years. Further, practice effect does not explain the verbal/nonverbal split at age 3 on the first exposure to DAS, nor the fact that the split does not widen across AEDs between age 3 and 4.5. In addition, several studies have found verbal impairments in children exposed to valproate, 17, 18, 22 and one other study reported that language functions were impaired in children with antenatal AED exposure. 26 Nevertheless, we caution that this finding requires replication in separate cohorts to determine if language abilities are particularly susceptible to fetal AED exposure. If this verbal impairment from fetal AED exposure is confirmed, it has important practical and theoretical implications.
Alcohol can induce widespread neuronal apoptosis in the immature brain, 27 raising concern that AEDs might produce similar effects. Some AEDs induce neuronal apoptosis in the immature brain when given in monotherapy, and many AEDs can enhance apoptosis in polytherapy. 28 -33 The effect is dose dependent, occurs at therapeutically relevant blood levels, and requires only relatively brief exposure. Valproate appears to induce the apoptosis at dosages relatively lower in terms of effective therapeutic dose compared to other AEDs. 28, 29 However, many AEDs have not been tested in this model. In regards to the induced cognitive deficits, the neuronal apoptosis likely only contributes in part, and the more important factor may be impaired physiology in the surviving neurons, similar to alcohol. 34 Although it is possible that widespread neuronal apoptosis or dysfunction might differentially affect verbal abilities, we have hypothesized that the greater verbal impairment might result from altered cerebral lateralization from fetal AED exposure. 23 Additional research is needed to test this hypothesis and fully delineate the mechanisms of behavioral teratogenesis.
The treatment of epilepsy in women of childbearing potential requires balancing risks that seizures pose to the mother and child vs risks of teratogenesis (i.e., congenital malformations and cognitive deficits) in the child. A discussion of these risks should occur prior to pregnancy in all women of childbearing potential treated with AEDs. Based on the current literature, valproate poses the most consistent, frequent, and severe risks for both anatomic and behavioral teratogenesis. 3, 6 We contend that valproate is a poor first choice AED for most women of child- Table 3 Adjusted a mean IQs, 95% CIs, DCIs, and p values b for comparisons to valproate, and sample sizes for each AED at age 4.5 years for ITT (n ‫؍‬ 310) and completer (n ‫؍‬ 209) analyses for each antiepileptic drug bearing potential. Some women with generalized epilepsy can only be controlled by valproate. 35 However, if other AEDs are ineffective in seizure control, then valproate can be used subsequently. When valproate is necessary, we recommend employing the lowest dose possible. Recent animal data suggest that peak drug levels may be an important risk factor for damage to the immature brain, 36 but there are inadequate human data to determine if multiple daily doses or extended release formulations would reduce risk. Our present knowledge remains inadequate on many issues to direct care of women with epilepsy who might become pregnant. 6, 37, 38 If teratogenetic issues alone are considered, fetal risks are not fully delineated for most AEDs in regards to malformations or cognitive outcomes. Investigations of both anatomic and behavioral teratogenesis in humans are based on observational studies. Thus, a signal needs to be observed in multiple cohorts, as is the case for valproate. The recent EURAP results show dosedependent malformation risks for not only valproate, but also carbamazepine, lamotrigine, and phenobarbital. 39 Teratogens act in a dose-dependent manner, and delineation of dose effects for both anatomic and functional deficits in other AEDs may require larger sample sizes than valproate. Further, the relative risks of specific polytherapy combinations are unknown. Understanding these effects is critical to management of women with epilepsy who are of childbearing potential.
Figure 1
Scatterplots of age 4.5 IQ vs standardized dose for each antiepileptic drug during pregnancy Abbreviations: AED ϭ antiepileptic drug; CI ϭ confidence interval. a Mean verbal and nonverbal cluster scores, and their mean differences using a linear model controlling for maternal IQ, dose, age of mother, gestational age, alcohol use, race/ethnicity, and years of maternal education. b Difference of nonverbal cluster minus verbal cluster. c p Values for paired t tests.
The risk for malformations is primarily due to exposure early in the first trimester, but the risk for cognitive deficits appears to be in the third trimester, similar to alcohol. While dose might be a reasonable surrogate for AED exposure early in pregnancy, it is not late in pregnancy due to considerable variability in AED clearance during pregnancy across AEDs and across individual patients. 40 To date, no study of outcomes in children of women with epilepsy have controlled for this factor by assessing AED blood levels, which would be a much better measure of intrauterine AED exposure. Further, it is critical that our observation of language deficits in 4 commonly used AEDs be examined in other cohorts and in additional AEDs. Given the evolving nature of our evidence base, clinicians and patients should remain attentive to future information and its implications.
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